Indication intelligence, analysis and sector perception

RMi’s closing bell analysis: the sector closed up after a struggle

May 27, 2016 5:07pm

Have a safe and enjoyable Memorial Day weekend …

The iShares Nasdaq Biotechnology ETF (IBB) traded more than half a percent higher.

Do you care what happened today, you should … because it has implications to Monday's sector activity?

There are two things that everyone needs interpretation and translation of intelligence, not just news or information - we get too much!

To that end, I report a matrix of variables designed for investor’s consideration concerning the stem, cell and gene therapy and regenerative medicine portfolio to track and monitor its pricing metric;

U.S. stocks traded slightly higher Friday, tracking for a solid week of gains ahead of the Memorial Day weekend, after comments from Fed Chair Yellen.

The NASDAQ closed UP +31.74 or +0.65% to 4,933.50 and the DOW closed UP +44.93 or +0.25% to 17,873.22.

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector – the advance/decline line scenario of our 43 covered companies.

Opened barely positive with an A/DL of 19/18 and 6 flats;

The mid-day slipped neutral with an A/DL of 20/20 with 3 flat;

The closing bell was positive with A/DL of 27/13 with 3 flats

Henry’omics:

Sector stocks opened barely positive, flipped neutral at the mid-day and closed positive.

Stem, cell and gene therapy and regenerative medicine sector stocks traded with lower volume, as expected!

Today’s Bottom Line:

The biggest problem investors face is the uncertainty of share pricing. So, which decisions are investors paying for – the ones that assist managements!

Review my fear gauge or the CBOE Volatility Index (VIX):

Friday traded near 13.3;
Thursday traded near 13.8;
Wednesday traded near 13.8;
Tuesday traded below 15;
Monday traded below 16
Last, Friday traded 15.5;

Most active sector stocks + and -:

Biostage (BSTG) -5.37%;
Neuralstem (CUR) -4.72%;
ReNeuron (RENE.L) -3.57%;
Caladrius Biosciences (CLBS) -3.57%;
uniQure (QURE) -2.28%;

Versus …

Stemline (STML) +15.02%;
Adverum (ADVM) +6.13%
Verastem (VSTM) +4.93%;
Bellicum (BLCM) +4.36%;
Organovo (ONVO) +3.69%

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

6 hours 5 min ago
RegMed Investors’ (RMi) pre-open: Are we ready for the 2nd half and resumption of the earnings cycle

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.